The broader socio-economic value of adult respiratory disease vaccinations in the UK – results from a benefit cost analysis
Adult respiratory vaccination delivers socio-economic benefits well beyond direct health-care savings, yet investment remains low. Considering broader impacts beyond standard cost-effectiveness can better align policy with public health and economic goals.
Authors
- Jeffrey Vietri (ORCID: https://orcid.org/0000-0002-5610-3098)
- Simon Brassel (ORCID: https://orcid.org/0000-0001-7574-9671)
- Tianyan Hu (ORCID: https://orcid.org/0009-0004-2660-8871)
- Cale Harrison
- Sulayman Chowdhury (ORCID: https://orcid.org/0000-0001-8468-2122)
- Diana Mendes (ORCID: https://orcid.org/0000-0002-1672-4906)
- Jingyan Yang (ORCID: https://orcid.org/0000-0001-5523-649X)
- Lotte Steuten (ORCID: https://orcid.org/0000-0002-5688-236X)
- Melanie Napier
- Claud Theakston (ORCID: https://orcid.org/0009-0008-6876-1523)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Office Of Health Economics (GB)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1080/14760584.2025.2536093
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer